Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00501735 | Forodesine in the Treatment of Cutaneous T-Cell Lymphoma | PHASE2 | COMPLETED | 144 | — | — | Jul 1, 2007 | Dec 1, 2011 | Jan 23, 2012 | 41 | United States, Australia +8 |
| Name | Type | Description |
|---|---|---|
| Forodesine 200 mg | DRUG | 2 x 100mg tablets once daily |
Inclusion Criteria: * Males or non-pregnant females aged ≥18 years; * Histologically confirmed diagnosis of CTCL, including mycosis fungoides and/or Sezary syndrome, documentation of diagnosis by histologic examination should be available; * Subjects with CTCL stages IB, IIA, IIB, III, or IVA at th...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Soligenix, Inc. | SNGX | 1 | PHASE3 | Hypericin |
| Incyte Corporation | INCY | 2 | PHASE2 | Ruxolitinib, Pembrolizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | — | Undisclosed |